Trials / Unknown
UnknownNCT05689203
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS1128 | dose 1 |
| DRUG | QLS1128 | dose 2 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-12-30
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
- First posted
- 2023-01-19
- Last updated
- 2023-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05689203. Inclusion in this directory is not an endorsement.